Perinatal impact of the use of metformin and glyburide for the treatment of gestational diabetes mellitus

Página do item simplificado
dc.contributor.authorSilva, Jean Carl
dc.contributor.authorRigon Narciso Fachin, Debora Raquel
dc.contributor.authorCoral, Morgana Leonora
dc.contributor.authorBertini, Anna Maria [UNIFESP]
dc.contributor.institutionUniv Regiao Joinville UNIVILLE
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.date.accessioned2016-01-24T14:27:06Z
dc.date.available2016-01-24T14:27:06Z
dc.date.issued2012-04-01
dc.description.abstractObjective : To evaluate the perinatal impact of metformin and glyburide in the treatment of gestational diabetes mellitus (GDM).Methods : A randomized clinical trial conducted from July 2008 until September 2010 studied 200 pregnant women with GDM who required adjunctive therapy to diet and physical activity. Patients were randomized to use metformin (n = 104) or glyburide (n = 96). the drugs were replaced by insulin when they reached the maximum dose without glycemic control. Assessed outcomes: weight and neonatal blood glucose.Results : No difference was found (P > 0.05) between the groups regarding maternal age, gestational age at inclusion, body mass index, glucose levels in oral glucose tolerance test (OGTT) 75 g and glycemic control. Difference was found in the number of previous pregnancies (2.84 vs. 2.47, P = 0.04) and weight gain during pregnancy (7.78 vs. 9.84, P = 0.04) in the metformin group and glyburide respectively. the perinatal results showed no difference (P > 0.05) in the percentage of cesarean deliveries, gestational age at delivery, number of newborns large for gestational age (LGA), neonatal hypoglycemia, admission to intensive care unit and perinatal death. We found differences in weight (3193 g vs. 3387 g, P = 0.01) and ponderal index (2.87 vs. 2.96, P = 0.05) of newborns, and in neonatal blood glucose levels at the 1st (59.78 vs. 54.08, P = 0.01) and 3rd h (61.53 vs. 55.89, P = 0.01) after birth between the metformin and glyburide groups respectively.Conclusions : Weight and ponderal index were lower in the newborns of the metformin group; glucose levels (1st and 3rd h after birth) were lower in the glyburide group.en
dc.description.affiliationUniv Regiao Joinville UNIVILLE, Dept Obstet, Joinville, Brazil
dc.description.affiliationUniversidade Federal de São Paulo, Dept Obstet, São Paulo, Brazil
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Dept Obstet, São Paulo, Brazil
dc.description.sourceWeb of Science
dc.format.extent225-228
dc.identifierhttp://dx.doi.org/10.1515/jpm-2011-0175
dc.identifier.citationJournal of Perinatal Medicine. Berlin: Walter de Gruyter & Co, v. 40, n. 3, p. 225-228, 2012.
dc.identifier.doi10.1515/jpm-2011-0175
dc.identifier.issn0300-5577
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/34785
dc.identifier.wosWOS:000303977800003
dc.language.isoeng
dc.publisherWalter de Gruyter & Co
dc.relation.ispartofJournal of Perinatal Medicine
dc.rightsAcesso restrito
dc.subjectBody mass indexen
dc.subjectgestational age at deliveryen
dc.subjectgestational diabetes mellitusen
dc.subjectglyburideen
dc.subjectintensive care unit, large for gestational ageen
dc.subjectmetforminen
dc.subjectoral glucose tolerance testen
dc.titlePerinatal impact of the use of metformin and glyburide for the treatment of gestational diabetes mellitusen
dc.typeArtigo
Arquivos
Coleções
EPM - Artigos